FORM 4
[ X ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

McLaughlin Gerald W. 		2. Issuer Name and Ticker or Trading Symbol

NUPATHE INC. [ PATH ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
SVP, Chief Commercial Officer
(Last)          (First)          (Middle)

C/O NUPATHE INC.,, 7 GREAT VALLEY PARKWAY, SUITE 300 		3. Date of Earliest Transaction (MM/DD/YYYY)

2/21/2014
(Street)

MALVERN, PA 19355
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   2/21/2014     U    11771   D $6.80   (1) 0   D    
Common Stock   (2) 2/21/2014     D    144880   D $6.80   (1) 0   D    

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock option (right to buy)   $1.44   2/21/2014     D         22707      (3) 9/20/2017   Common Stock   22707   $5.36   (4) 0   D    
Stock option (right to buy)   $1.92   2/21/2014     D         57054      (3) 9/11/2018   Common Stock   57054   $4.88   (4) 0   D    
Stock option (right to buy)   $1.92   2/21/2014     D         5988      (3) 1/29/2019   Common Stock   5988   $4.88   (4) 0   D    

Explanation of Responses:
( 1)  Disposed upon the consummation of the merger (the "Merger") contemplated by the Agreement and Plan of Merger, dated January 17, 2014, among the issuer, Teva Pharmaceutical Industries Ltd. and Train Merger Sub, Inc.(the "Merger Agreement"), in exchange for $3.65 per share, plus contractual rights to receive up to an additional $3.15 in contingent cash consideration payments per share.
( 2)  Includes all restricted stock units and all restricted stock awards that became fully vested upon the consummation of the Merger.
( 3)  Pursuant to the Merger Agreement, all options became fully vested upon the consummation of the Merger.
( 4)  Pursuant to the Merger Agremeent, the option was converted into the right to receive, at the earliest date at which the sum of (1) the $3.65 per share cash portion of the merger consideration and (2) the amount per share in cash previously paid or to be paid at such date in connection with the Contingent Cash Consideration Agreement entered into in connection with the Merger Agreement (such sum, the "Per Share Paid Value") exceeds the per-share exercise price under the option: (x) an amount in cash equal to the number of shares of common stock subject to the option multiplied by the excess of (i) the then applicable Per Share Paid Value over (ii) the per-share exercise price under the option; and (y) the right to receive, in respect of each share of common stock subject to the option, each contingent cash consideration payment that, as of such date, has not yet become payable.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
McLaughlin Gerald W.
C/O NUPATHE INC.,
7 GREAT VALLEY PARKWAY, SUITE 300
MALVERN, PA 19355

SVP, Chief Commercial Officer

Signatures
/s/ Michael F. Marino, attorney-in-fact 2/25/2014
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Nupathe Inc. (MM) (NASDAQ:PATH)
Historical Stock Chart
From Dec 2024 to Jan 2025 Click Here for more Nupathe Inc. (MM) Charts.
Nupathe Inc. (MM) (NASDAQ:PATH)
Historical Stock Chart
From Jan 2024 to Jan 2025 Click Here for more Nupathe Inc. (MM) Charts.